[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 6 of about 6
1. Nishio S, Morioka T, Fujii K, Inamura T, Fukui M: Spinal cord gliomas: management and outcome with reference to adjuvant therapy. J Clin Neurosci; 2000 Jan;7(1):20-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord gliomas: management and outcome with reference to adjuvant therapy.
  • The authors review their experience with 19 consecutive cases with either astrocytic tumour (glioblastoma multiforme one, anaplastic astrocytoma one, astrocytoma 4, pilocytic astrocytoma 4) or ependymoma (10 tumours in 9 patients) of the spinal cord who were treated during the period from 1982 to 1996.
  • The main tumour locations included the cervicomedullary region 5 the cervical cord (8), the thoracic cord (5) and one each in the thoracolumbar region and conus medullaris.
  • [MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child, Preschool. Female. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Infant. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10847645.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SCOTLAND
  •  go-up   go-down


2. MacDonald TJ, Arenson EB, Ater J, Sposto R, Bevan HE, Bruner J, Deutsch M, Kurczynski E, Luerssen T, McGuire-Cullen P, O'Brien R, Shah N, Steinbok P, Strain J, Thomson J, Holmes E, Vezina G, Yates A, Phillips P, Packer R: Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer; 2005 Dec 15;104(12):2862-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were randomly assigned to one of three couplets of drugs: carboplatin/etoposide (Regimen A), ifosfamide/etoposide (Regimen B), or cyclophosphamide/etoposide (Regimen C).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Neoadjuvant Therapy
  • [MeSH-minor] Adolescent. Adult. Brain Stem Neoplasms / drug therapy. Brain Stem Neoplasms / mortality. Brain Stem Neoplasms / pathology. Brain Stem Neoplasms / radiotherapy. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Radiotherapy, High-Energy. Reference Values. Risk Assessment. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / mortality. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / radiotherapy. Survival Analysis. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16315242.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


3. Clavo B, Robaina F, Morera J, Ruiz-Egea E, Pérez JL, Macías D, Caramés MA, Catalá L, Hernández MA, Günderoth M: Increase of brain tumor oxygenation during cervical spinal cord stimulation. Report of three cases. J Neurosurg; 2002 Jan;96(1 Suppl):94-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increase of brain tumor oxygenation during cervical spinal cord stimulation. Report of three cases.
  • Malignant brain tumors have been shown to decrease O2 and blood flow resulting in hypoxia and low perfusion that in turn reduce radiation sensitivity and access by chemotherapeutic agents.
  • Spinal cord stimulation (SCS) is a procedure that has been used quite successfully in the treatment of pain and ischemic syndromes.
  • [MeSH-major] Astrocytoma / blood supply. Brain Neoplasms / blood supply. Cell Hypoxia / physiology. Electric Stimulation Therapy. Glioblastoma / blood supply. Glioma / blood supply. Oxygen Consumption / physiology. Spinal Cord / physiopathology
  • [MeSH-minor] Adult. Aged. Cerebral Cortex / blood supply. Cerebral Cortex / radiation effects. Cerebral Cortex / surgery. Combined Modality Therapy. Electrodes, Implanted. Female. Humans. Male. Middle Aged. Polarography. Radiotherapy, Adjuvant. Regional Blood Flow / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11795721.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Poelen J, Bernsen HJ, Prick MJ: Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg; 2007 Jun;107(2):51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic medulloblastoma in an adult; treatment with temozolomide.
  • Treatment of this tumour type usually consists of surgery followed by radiotherapy.
  • A medulloblastoma at adult age is extremely rare, and there is no overall accepted treatment, especially not in the case of a relapse.
  • Recently improvement of survival was reported in patients with glioblastoma treated with a combination of radiotherapy and concomitant temozolomide.
  • This observation encouraged us to decide to treat an adult patient with a recurrent medulloblastoma with temozolomide.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cerebellar Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710841.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


5. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH: Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol; 2010 Oct;66(5):927-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors.
  • METHODS: Tamoxifen 100 mg po bid, topotecan 0.25, 0.5, 0.75, or 1.0 mg/m(2)/d IV, administered as a 72 h continuous infusion on days 1-3, followed by carboplatin AUC = 3, IV on day 3.
  • The tumors included glioblastoma (6), anaplastic astrocytoma (2), metastatic non-small cell (3), small cell lung (2), and one each with medulloblastoma, ependymoma, and metastatic breast or colon carcinoma.
  • CONCLUSIONS: The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0.75 mg/m(2)/d IV continuous infusion for 72 h, followed by carboplatin AUC = 3 IV on day 3.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Anticancer Drugs. 1998 Aug;9(7):581-6 [9773800.001]
  • [Cites] J Neurooncol. 1999 Feb;41(3):285-9 [10359149.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):208-15 [18316473.001]
  • [Cites] Eur J Pharmacol. 2001 Jan 19;412(1):21-5 [11166732.001]
  • [Cites] Cancer Invest. 2002;20(3):293-302 [12025223.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Cancer. 1982 Jan 1;49(1):12-8 [6274499.001]
  • [Cites] Onkologie. 1983 Apr;6(2):58-61 [6223253.001]
  • [Cites] J Neurooncol. 1983;1(2):139-44 [6678966.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):382-8 [3417367.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):382-3 [2407368.001]
  • [Cites] Br J Cancer. 1991 Apr;63(4):641-5 [2021551.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18):4837-44 [1893376.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):173-7 [1716670.001]
  • [Cites] Cancer. 1992 Feb 15;69(4):972-80 [1735089.001]
  • [Cites] Cancer Metastasis Rev. 1991 Dec;10(4):335-41 [1786634.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3 [1377370.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(4):251-60 [1643692.001]
  • [Cites] Invest New Drugs. 1992 Nov;10(4):239-53 [1487397.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):485-9; discussion 489-90 [8384328.001]
  • [Cites] Eur J Cancer. 1993;29A(12):1696-9 [7691116.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(3):195-202 [8529278.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):734-41 [8637027.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(2):215-20 [8686548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):527-31 [8697400.001]
  • [Cites] J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):309-15 [8738036.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):587-90; discussion 590-1 [8837815.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3074-84 [8955652.001]
  • [Cites] Am J Clin Oncol. 1997 Jun;20(3):303-7 [9167759.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):161-7 [9266454.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-52-S12-55 [9331122.001]
  • [Cites] Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-11-S20-26 [9425957.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(4):307-16 [9488600.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(5):385-90 [9523734.001]
  • [Cites] J Neurooncol. 1998 May;38(1):59-68 [9540058.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1998 May;78(1):91-3 [9605456.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • (PMID = 20107803.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / P30 CA033572-26; United States / NCI NIH HHS / CA / CA 33572
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS335377; NLM/ PMC3265324
  •  go-up   go-down


6. Schor NF: Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther; 2009 Mar;121(3):253-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the adult central nervous system are among the most common and most chemoresistant neoplasms.
  • Malignant tumors of the brain and spinal cord collectively account for approximately 1.3% of all cancers and 2.2% of all cancer-related deaths.
  • Novel pharmacological approaches to nervous system tumors are urgently needed.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2008 Sep;15(3):721-43 [18753362.001]
  • [Cites] J Neurooncol. 2002 Jun;58(2):115-23 [12164682.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2725-34 [12171906.001]
  • [Cites] Anticancer Res. 2002 Jul-Aug;22(4):2029-36 [12174880.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1113-9 [12209698.001]
  • [Cites] Chemotherapy. 2002 Sep;48(4):189-95 [12218266.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):3008-18 [12231548.001]
  • [Cites] Glia. 2002 Oct;40(1):44-54 [12237842.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Dec;50(6):479-89 [12451475.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):599-602 [12649108.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):525-36 [12687909.001]
  • [Cites] Neuroimaging Clin N Am. 2002 Nov;12(4):583-97 [12687913.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2B):1631-5 [12820433.001]
  • [Cites] Curr Opin Oncol. 2003 Nov;15(6):412-8 [14624222.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):7875-83 [15585620.001]
  • [Cites] Lancet Neurol. 2005 Jan;4(1):4-5 [15620846.001]
  • [Cites] J Neurol Sci. 2005 Feb 15;228(2):143-7 [15694195.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):295-9 [15735920.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):301-5 [15735921.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4195-203 [15736473.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2411-22 [15800333.001]
  • [Cites] Neurology. 2005 Apr 26;64(8):1444-5 [15851741.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Front Biosci. 2005;10:2645-68 [15970525.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):135-41 [15994755.001]
  • [Cites] J Neurosurg. 2005 Jun;102(6):1170; author reply 1170-1 [16028784.001]
  • [Cites] Oncogene. 2005 Aug 4;24(33):5226-34 [15897911.001]
  • [Cites] Neurochem Int. 2005 Nov;47(6):430-41 [16087277.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1293-302 [16170020.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):113-21 [16193381.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):74-86 [16356833.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11419-28 [16357150.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):172-9 [16323194.001]
  • [Cites] Pituitary. 2005;8(1):43-52 [16411068.001]
  • [Cites] Pituitary. 2005;8(1):53-60 [16411069.001]
  • [Cites] BMC Cancer. 2006;6:2 [16393339.001]
  • [Cites] Eur J Endocrinol. 2006 Mar;154(3):467-77 [16498061.001]
  • [Cites] Eur Spine J. 2006 Feb;15(2):203-10 [16374649.001]
  • [Cites] J Endocrinol Invest. 2006 Jan;29(1):86-93 [16553040.001]
  • [Cites] J Cell Physiol. 2006 Jul;208(1):220-8 [16575905.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4687-92 [16651420.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2716-29 [16675563.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E22 [16709028.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E24 [16709030.001]
  • [Cites] Neurosurg Focus. 2006;20(4):E7 [16709038.001]
  • [Cites] Cell Death Differ. 2006 Jul;13(7):1238-41 [16456578.001]
  • [Cites] Oncol Rep. 2006 Jul;16(1):127-32 [16786135.001]
  • [Cites] Front Horm Res. 2006;35:129-34 [16809928.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104 [16831080.001]
  • [Cites] Endocr Rev. 2006 Aug;27(5):485-534 [16705142.001]
  • [Cites] Anticancer Drugs. 2006 Aug;17(7):733-51 [16926624.001]
  • [Cites] Nat Clin Pract Neurol. 2005 Dec;1(2):88-95 [16932504.001]
  • [Cites] BMC Complement Altern Med. 2006;6:27 [16914050.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):271-9 [16645721.001]
  • [Cites] Glia. 2006 Dec;54(8):850-60 [16981197.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1295-301 [17016664.001]
  • [Cites] Oncol Rep. 2006 Nov;16(5):1117-21 [17016602.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Oct;2(10):552-61 [17024154.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1424-34 [16971507.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1585-92 [17134363.001]
  • [Cites] NMR Biomed. 2006 Dec;19(8):1035-42 [16894643.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):373-80 [18413337.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):699-706 [18338171.001]
  • [Cites] Neurology. 2008 Jul 29;71(5):365-73 [18663182.001]
  • [Cites] J Neurooncol. 2003 Oct;65(1):77-85 [14649887.001]
  • [Cites] Pituitary. 2003;6(1):19-27 [14674720.001]
  • [Cites] Lancet Oncol. 2004 Feb;5(2):89-100 [14761812.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):927-31 [14967452.001]
  • [Cites] Clin Neuropathol. 2004 Jan-Feb;23(1):21-7 [14986930.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1712-6 [15073861.001]
  • [Cites] Neuroendocrinology. 2004 Mar;79(3):142-8 [15103227.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E13 [15323470.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):201-6 [15354403.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1127-35 [15367707.001]
  • [Cites] J Neurosurg. 2004 Oct;101(4):653-8 [15481721.001]
  • [Cites] J Neurosurg. 2004 Nov;101(5):826-31 [15540922.001]
  • [Cites] J Inorg Biochem. 2004 Dec;98(12):2168-73 [15541507.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] J Clin Neurosci. 2007 Mar;14(3):261-6 [17258135.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):960-9 [17342095.001]
  • [Cites] Clin Neurosurg. 2006;53:345-51 [17380773.001]
  • [Cites] Curr Pharm Biotechnol. 2007 Apr;8(2):105-13 [17430159.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):639-52 [17440165.001]
  • [Cites] Ann Neurol. 2007 May;61(5):484-90 [17469128.001]
  • [Cites] J Mol Med (Berl). 2007 May;85(5):497-509 [17221219.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4467-73 [17483362.001]
  • [Cites] Neurology. 2007 May 22;68(21):1831-6 [17515545.001]
  • [Cites] J Neurochem. 2007 Jul;102(2):522-38 [17596214.001]
  • [Cites] Ann Endocrinol (Paris). 2007 Jun;68(2-3):118-9 [17512893.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72 [17646646.001]
  • [Cites] Mol Cancer Ther. 2007 Aug;6(8):2290-302 [17699724.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350 [17721049.001]
  • [Cites] J Neurooncol. 2007 Oct;85(1):1-10 [17429576.001]
  • [Cites] Bull Cancer. 2007 Sep;94(9):769-73 [17878096.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):643-53 [10690550.001]
  • [Cites] Acta Neuropathol. 2000 May;99(5):555-62 [10805101.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):20-3 [10847645.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2247-52 [10852458.001]
  • [Cites] J Neurooncol. 2000;46(2):157-71 [10894369.001]
  • [Cites] Int J Oncol. 2000 Sep;17(3):501-5 [10938390.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Ann Endocrinol (Paris). 2000 Nov;61(5):411-7 [11084391.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):449-62 [11139374.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):357-62 [11144529.001]
  • [Cites] Neurosurgery. 2001 Jan;48(1):151-7 [11152340.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):105-15 [11206006.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):117-29 [11206007.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):211-9 [11223551.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jan;86(1):140-5 [11231991.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):227-37 [11263502.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):930-8 [11313183.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3809-14 [11502816.001]
  • [Cites] Cancer Gene Ther. 2001 Aug;8(8):589-98 [11571537.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1077-83 [11592782.001]
  • [Cites] J Neuroimmunol. 2001 Nov 1;120(1-2):19-24 [11694315.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5256-61 [11701688.001]
  • [Cites] Curr Opin Neurol. 2001 Dec;14(6):679-82 [11723373.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):552-60 [11905710.001]
  • [Cites] Neurology. 2002 Apr 23;58(8):1310-1 [11971113.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Med Oncol. 2002;19(1):1-9 [12025885.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Jun;11(6):787-800 [12036422.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):397-406 [12142169.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4307-15 [12154034.001]
  • (PMID = 19091301.001).
  • [ISSN] 0163-7258
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS038569; United States / NINDS NIH HHS / NS / NS038569-10; United States / NCI NIH HHS / CA / CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289; United States / NINDS NIH HHS / NS / R01 NS038569-10
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 132
  • [Other-IDs] NLM/ NIHMS103661; NLM/ PMC2782733
  •  go-up   go-down






Advertisement